• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
155950 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  4 }$ N/ O, }5 a- A# D

2 ?# j# y5 b! r: e. H4 ^* ^" C% f6 \& ]; {7 Q/ E
Sub-category:
- K; R5 E% r; e  ]! E- k) w7 L+ jMolecular Targets ! c( n' I4 q8 t' p2 `$ Y
* U2 y  x# I4 a" I* ?

- B# B4 n" d! j, h2 @  d6 k! Y+ kCategory:
5 [* a$ T+ ^% W4 i' W6 cTumor Biology
) W* P1 O( L, Y8 {9 Y2 W2 ?6 }3 k: ?# z! J
- q2 Q0 M9 [" d" w/ G1 e9 }# X
Meeting:1 H9 X* E7 [4 J
2011 ASCO Annual Meeting
8 J+ F5 g1 ~- x9 g. ^1 x' D$ ^: K8 ^9 a4 l/ q

: k' o1 b' P/ @: {  A* [Session Type and Session Title:' B$ b6 p9 ], ?& S6 j
Poster Discussion Session, Tumor Biology ( o9 Q9 w  E2 a

/ Y# S/ F1 s$ C8 u  a
3 y# |/ L% h& Y% C& T* TAbstract No:
! D/ l( J9 O8 _6 ~$ Z  k: w10517
9 e( v" G6 K7 q8 y5 J2 k* x+ S  ^+ S; S% b1 n! Y9 f6 |
0 ?; d8 i; m4 f( v5 x
Citation:
  H5 S  R+ K( z+ o) d3 w4 R- dJ Clin Oncol 29: 2011 (suppl; abstr 10517)
$ u& k: p* e9 `4 _9 B4 T+ h! q5 u8 V, I3 `2 l: S) X& d

% R% h9 P' H+ r% v1 K2 `/ D  }Author(s):
2 T- l8 d2 ^' L% CJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ' F& c5 C3 P% Z) K' B7 j
6 n0 h+ ?) Z; s6 H6 C7 d
+ \3 R" W4 [) ]/ ~. _
0 x3 L6 B: }' z* |% n4 o
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.) k! |' t$ Z+ C1 a/ z: M
2 _% ^( l+ p( S+ h2 ~$ U+ \& h, k
Abstract Disclosures
7 D$ S8 ^! W- P! y4 i/ ?
9 C( P  C/ `+ U$ `. F. A# H8 \Abstract:5 k' u; X; E6 a* x" O) h
  I! T) @( S2 B" d* {& b0 ?- R

0 V+ N2 m% t. W+ x* i: X2 ~7 x1 i" W  \Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 @) @0 H* z3 P6 A1 a. C* W4 b+ D/ E1 M/ k7 D1 B* P1 z: a) z- c
5 r, y) o4 Q/ x. ?0 J' K3 A0 _
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 * n9 n- I! A0 \
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

( Z! M: V6 `* O- ]: r. m. y$ |化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
- ?6 Z5 z! k$ ~$ _易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。- r  j( ]. {0 S* V1 M# h: m- H
ALK一个指标医院要900多 ...

3 {6 ~( \' U  ]' \: Q2 q4 B平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
  Y3 f1 ^- D- |
/ X) L( Q8 t* G6 V4 J现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表